Effects of a new thyrotropin-releasing hormone analogue administered in rats 1 week after middle cerebral artery occlusion.
We observed the effects of a new thyrotropin-releasing hormone analogue, YM-14673 (N alpha-[[(S)-4-oxo-2-azetidinyl]carbonyl]-L-histidyl-L-prolinamide dihydrate) on behavioral changes in 26 rats subjected to middle cerebral artery occlusion. The administration of 0.1 mg/kg i.p. YM-14673 was started 1 week after occlusion and was repeated daily for 2 weeks. YM-14673 significantly accelerated the recovery of neurologic deficits and ameliorated the disturbance of passive avoidance learning. Thus, YM-14673 improved behavioral response in a model of chronic focal cerebral ischemia. The availability of a chronic middle cerebral artery occlusion model for the evaluation of drugs is also discussed.
Department of Pharmacology, Yamanouchi Pharmaceutical Co. Ltd., Tokyo, Japan.
M
M
Yamamoto
A
A
Tamura
T
T
Kirino
M
M
Hirakawa
M
M
Shimizu
K
K
Sano
D000818:Animals; D001362:Avoidance Learning / Q000187:drug effects*; D001384:Azetidines / Q000627:therapeutic use*; D001385:Azetines / Q000627:therapeutic use*; D001522:Behavior, Animal / Q000187:drug effects*; D002536:Cerebral Arteries / Q000502:physiology; D003250:Constriction; D004151:Dipeptides / Q000627:therapeutic use*; D002546:Ischemic Attack, Transient / Q000188:drug therapy* / Q000209:etiology; D008297:Male; D051381:Rats; D011919:Rats, Inbred Strains; D013997:Time Factors
D001384:Azetidines; D001385:Azetines; D004151:Dipeptides; C054995:azetirelin